COO

AI Memo

Cooper Companies

As of 2026-09-10/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q3 FY2026 print and guidance reset • 2026-09-09

Base target: $69 / p=50% prob

Biggest risk

The market reaction appears focused on weak forward visibility: CooperVision was flat in Q3, channel-inventory pressure extends into Q4, Q4 total organic growth is guided to 0%-2%, and non-GAAP gross margin declined 60 basis points year over year. The strategic review retained CooperSurgical rather than delivering an immediate sale or separation catalyst.

Invalidation

Break below $54 or thesis failure.

What would change my mind?

Q3 non-GAAP EPS exceeded expectations, free cash flow was strong, fertility growth remained solid, and the expanded buyback may support valuation. Strategic-review initiatives could improve execution and longer-term growth.

Research note

Recommendation

—

Confidence

high

As of

2026-09-10

Base target

$69

p=50%

Bull target

$81

p=25%

Bear target

$54

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

CooperVision inventory digestion
Strategic-review execution and capital allocation
Q3 non-GAAP EPS exceeded expectations, free cash flow was strong, fertility growth remained solid, and the expanded buyback may support valuation.

BearKey bullets

CooperVision Asia Pacific revenue declined 5% organically in Q3, while Americas revenue declined 2% organically.
[#SEC-8K-2026-09-09]
CooperVision U.S.

WatchKey bullets

Q3 FY2026 print and guidance reset

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $69 (p=50%)

Target spread vs base: +17% / -22%

Scenario probabilities

Bull Target: $81 (p=25%)Base Target: $69 (p=50%)Bear Target: $54 (p=25%)

Commentary

Post-print coverage is negative around weak guidance and the CooperVision inventory overhang, despite a Q3 earnings beat, strong free cash flow, and buyback expansion. No reliable post-print analyst target changes, estimate revisions, options data, short-interest data, employee sentiment, or social coverage were supplied; confidence is therefore moderated. The prior bullish monitoring thesis has shifted to cautious event-driven monitoring.

As of 2026-09-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

CooperVision inventory digestion
Strategic-review execution and capital allocation

Scenarios

Bull Target (Scenario probability)

$81 / p=25% prob

Base Target (Scenario probability)

$69 / p=50% prob

Bear Target (Scenario probability)

$54 / p=25% prob

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-09
Q3 FY2026 print and guidance reset
Revenue rose 1% to $1.066 billion, non-GAAP EPS rose 4% to $1.15, and free cash flow rose 66% to $273 million. However, CooperVision was flat and management expects Q4 CooperVision organic growth of -2% to 0% and Q4 non-GAAP EPS of $1.05-$1.09. [#SEC-8K-2026-09-09]
Prob 100.00% • Move -4.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

CooperVision inventory digestion
2026-10-31
Management said proactive U.S. channel-inventory reduction weighed on Q3 results and will continue affecting Q4, creating near-term execution and estimate-risk pressure. [#SEC-8K-2026-09-09]
Prob 85% • Move -5% • Priced-in 55%

Long-term Catalysts

Months to a year

Strategic-review execution and capital allocation
2026-09-23
The Board retained CooperSurgical, expanded the repurchase authorization from $2 billion to $3 billion, and outlined commercial, efficiency, logistics, and innovation initiatives. CooperVision’s Vision Centre is scheduled to open September 23, 2026. [#SEC-8K-2026-09-09]
Prob 55% • Move 6% • Priced-in 40%

Risks

CooperVision Asia Pacific revenue declined 5% organically in Q3, while Americas revenue declined 2% organically. [#SEC-8K-2026-09-09]
CooperVision U.S. channel-inventory reduction is expected to continue affecting Q4. [#SEC-8K-2026-09-09]
Non-GAAP gross margin declined 60 basis points year over year because of higher manufacturing costs and unfavorable foreign exchange. [#SEC-8K-2026-09-09]
Q4 guidance implies CooperVision organic growth of -2% to 0% and total non-GAAP EPS of $1.05-$1.09. [#SEC-8K-2026-09-09]
The strategic review cited a competitive entrant in the non-hormonal IUD market and fertility litigation settlement effects as valuation headwinds. [#SEC-8K-2026-09-09]

Peers

Symbol	Summary
BSX	Large medical-device reference with stronger cardiovascular exposure; useful sector context but not a close CooperVision or CooperSurgical comparable.
EW	Procedure-driven medtech reference; relevant for device-sector sentiment, but business mix and growth drivers differ materially from Cooper.
ABT	Diversified healthcare reference with broad medtech exposure; useful for sector context but not a clean direct peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-10

Loading AI feed…

Symbol

Summary

BSX

Large medical-device reference with stronger cardiovascular exposure; useful sector context but not a close CooperVision or CooperSurgical comparable.

Procedure-driven medtech reference; relevant for device-sector sentiment, but business mix and growth drivers differ materially from Cooper.

ABT

Diversified healthcare reference with broad medtech exposure; useful for sector context but not a clean direct peer.